Pain – CI

The correct answer is Hypersensitivity (eg, anaphylactic shock) to buprenorphine, naloxone, or any component of the formulation.

The correct answer is Concomitant therapy with ciprofloxacin or fluvoxamine (potent CYP1A2 inhibitors)

The correct answer is Hypersensitivity (eg, anaphylaxis) to morphine or any component of the formulation; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days; GI obstruction, including paralytic ileus (known or suspected).

The correct answer is
Hypersensitivity to fentanyl or any component of the formulation; respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; gastrointestinal obstruction, including paralytic ileus (known or suspected); management of acute or intermittent pain, postoperative or mild pain; patients who are not opioid tolerant; acute pain management in the emergency room.

The correct answer is Hypersensitivity (eg, anaphylaxis) to hydrocodone or any component of the formulation; GI obstruction, including paralytic ileus (known or suspected); significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment.

The correct answer is Hypersensitivity (eg, anaphylaxis) to methadone or any component of the formulation; significant respiratory depression (in the absence of resuscitative equipment or in unmonitored settings); acute or severe bronchial asthma (in the absence of resuscitative equipment or in an unmonitored setting); hypercarbia; GI obstruction, including paralytic ileus (known or suspected)

The correct answer is Hypersensitivity (eg, anaphylaxis, angioedema) to oxycodone or any component of the formulation; significant respiratory depression; hypercapnia; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; GI obstruction, including paralytic ileus (known or suspected).

The correct answer is Hypersensitivity (eg, anaphylaxis) to tramadol, opioids, or any component of the formulation; pediatric patients <12 years of age; postoperative management in pediatric patients <18 years of age who have undergone tonsillectomy and/or adenoidectomy; significant respiratory depression; acute or severe bronchial asthma in the absence of appropriately monitored settings and/or resuscitative equipment; GI obstruction, including paralytic ileus (known or suspected); concomitant use with or within 14 days following monoamine oxidase inhibitor therapy.

The correct answer is Hypersensitivity (eg, anaphylaxis) to codeine or any component of the formulation; pediatric patients <12 years of age; postoperative management in pediatric patients <18 years of age who have undergone tonsillectomy and/or adenoidectomy; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; GI obstruction, including paralytic ileus (known or suspected); concurrent use with monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days

The correct answer is
Hypersensitivity to baclofen or any component of the formulation
Intrathecal formulation: IV, IM, SubQ, or epidural administration

The correct answer is Hypersensitivity to cyclobenzaprine or any component of the formulation; during or within 14 days of MAO inhibitors; hyperthyroidism; heart failure; arrhythmias; heart block or conduction disturbances; acute recovery phase of MI

The correct answer is Hypersensitivity to carbamates (eg, meprobamate), or any component of the formulation; history of acute intermittent porphyria

The correct answer is Hypersensitivity to metaxalone or any component of the formulation; significantly impaired hepatic or renal function, tendency to drug-induced, hemolytic, or other anemias

The correct answer is Hypersensitivity to methocarbamol or any component of the formulation; renal impairment (injection formulation)

The correct answer is Ischemic coronary artery disease (eg, angina pectoris, history of myocardial infarction, documented silent ischemia); coronary artery vasospasm, including Prinzmetal angina; Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders; history of stroke, transient ischemic attack, or history or current evidence of hemiplegic or basilar migraine; peripheral vascular disease; ischemic bowel disease; uncontrolled hypertension; recent use (within 24 hours) of treatment with another 5-HT1 agonist, or an ergotamine-containing or ergot-type medication (eg, dihydroergotamine or methysergide); recent use (within at least 72 hours) of the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir; known hypersensitivity to eletriptan or any component of the formulation.

The correct answer is Hypersensitivity (eg, angioedema, anaphylaxis) to sumatriptan or any component of the formulation; ischemic heart disease or signs or symptoms of ischemic heart disease (coronary artery vasospasm, Prinzmetal angina, angina pectoris, MI, silent myocardial ischemia); history of cerebrovascular syndromes (including strokes, transient ischemic attacks), history of hemiplegic or basilar migraine; peripheral vascular disease (including ischemic bowel disease); uncontrolled hypertension; use within 24 hours of ergotamine derivatives; use within 24 hours of another 5-HT1 agonist; concurrent administration or within 2 weeks of discontinuing an MAO type A inhibitors; Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders; severe hepatic impairment (excluding Sumavel)